<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04780737</url>
  </required_header>
  <id_info>
    <org_study_id>RAC 164/2017/ O/Oss</org_study_id>
    <nct_id>NCT04780737</nct_id>
  </id_info>
  <brief_title>Prophylactic Cholecystectomy is Not Mandatory in Patients Candidate to the Resection for Small Intestine Neuroendocrine Neoplasms: a Propensity Score-matched and Cost-minimization Analysis</brief_title>
  <official_title>Prophylactic Cholecystectomy is Not Mandatory in Patients Candidate to the Resection for Small Intestine Neuroendocrine Neoplasms: a Propensity Score-matched and Cost-minimization Analysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IRCCS Azienda Ospedaliero-Universitaria di Bologna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IRCCS Azienda Ospedaliero-Universitaria di Bologna</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate two competitive strategies in patients undergoing resection of Small-intestine&#xD;
      Neuroendocrine neoplasms (Si-NEN): Prophylactic Cholecystectomy (PC) versus On-demand delayed&#xD;
      cholecystectomy&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a retrospective study based on 230 Si-NENs candidates to the primary tumor resection.&#xD;
      Patients were divided into two arms: PC and OC. Propensity score matching was performed,&#xD;
      reporting the d value. The primary outcome was the re-hospitalization rate for any cause. The&#xD;
      secondary endpoints were the re-hospitalization rate for biliary stone disease (BSD), the&#xD;
      mean number of re-hospitalization (any cause and BSD), the complication rate (all and&#xD;
      severe), and the total costs. A P-value &lt; 0.05 was considered significant, and NNT&lt; 10 was&#xD;
      considered clinically relevant.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2000</start_date>
  <completion_date type="Actual">July 2020</completion_date>
  <primary_completion_date type="Actual">December 2019</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>re-hospitalization rate for any cause</measure>
    <time_frame>through study completion, an average of 7 years</time_frame>
    <description>the re-hospitalization rate for any cause after primary tumor surgery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>re-hospitalization rate for biliary stone disease</measure>
    <time_frame>through study completion, an average of 7 years</time_frame>
    <description>the re-hospitalization rate for biliary stone disease after primary tumor surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mean number of re-hospitalization any cause</measure>
    <time_frame>through study completion, an average of 7 years</time_frame>
    <description>the mean number of re-hospitalization for any cause after primary tumor surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mean number of re-hospitalization biliary stone disease</measure>
    <time_frame>through study completion, an average of 7 years</time_frame>
    <description>the mean number of re-hospitalization for biliary stone disease after primary tumor surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>total costs</measure>
    <time_frame>through study completion, an average of 7 years</time_frame>
    <description>total costs for primary tumor surgery plus any re-hospitalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>COmplication rate</measure>
    <time_frame>through study completion, an average of 7 years</time_frame>
    <description>COmplication rate after primary tumor resection</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">230</enrollment>
  <condition>Neuroendocrine Tumors</condition>
  <condition>Surgery</condition>
  <condition>Gut Tumor</condition>
  <arm_group>
    <arm_group_label>Prophylactic cholecystectomy</arm_group_label>
    <description>Patient who undergo resection of primary ileal neuroendocrine tumor and contemporarly cholecystectomy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>On-demand cholecystectomy</arm_group_label>
    <description>Patient resected for primary ileal neuroendocrine tumor, treated with cholecystectomy in a different operation and only if needed, for the development of biliary stone disease</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cholecystectomy</intervention_name>
    <description>Laparoscopic or laparotomic cholecystectomy</description>
    <arm_group_label>On-demand cholecystectomy</arm_group_label>
    <arm_group_label>Prophylactic cholecystectomy</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        For each patient sex, age, comorbidity, presence of symptoms, type of surgery (emergency or&#xD;
        elective), ENETS TNM stage, WHO 2019 grading of the primary tumor, type of resection (R0/1&#xD;
        vs. R2), administration of SSA therapy, duration of follow-up, were collected&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients with a diagnosis of Si-NEN;&#xD;
&#xD;
          -  resection of the primary tumor with or without concomitant cholecystectomy;&#xD;
&#xD;
          -  absence of a history of a biliary stone disease or cholecystectomy before Si-NEN&#xD;
             diagnosis&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        - presence of a history of a biliary stone disease or cholecystectomy before Si-NEN&#xD;
        diagnosis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carlo Ingaldi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Azienda Ospedaliero Universitaria, Ospedale S.Orsola Malpighi</affiliation>
  </overall_official>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>January 8, 2021</study_first_submitted>
  <study_first_submitted_qc>March 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 3, 2021</study_first_posted>
  <last_update_submitted>March 2, 2021</last_update_submitted>
  <last_update_submitted_qc>March 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>IRCCS Azienda Ospedaliero-Universitaria di Bologna</investigator_affiliation>
    <investigator_full_name>Carlo Ingaldi, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Neuroendocrine Tumors</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

